Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$1.01B |
| 2 |
e.l.f. Beauty
ELF
|
+$324M |
| 3 |
DraftKings
DKNG
|
+$263M |
| 4 |
Pinduoduo
PDD
|
+$226M |
| 5 |
Datadog
DDOG
|
+$204M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.68B |
| 2 |
NVIDIA
NVDA
|
+$1.46B |
| 3 |
Spotify
SPOT
|
+$1.03B |
| 4 |
Mercado Libre
MELI
|
+$765M |
| 5 |
Moody's
MCO
|
+$593M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 31.34% |
| 2 | Technology | 28.05% |
| 3 | Communication Services | 17.02% |
| 4 | Healthcare | 9.5% |
| 5 | Financials | 5.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
McDonald's
MCD
$195B
| $42.9M | 0.03% |
147,954
+9,799
| +7% | +$2.92M |
|
152
Medtronic
MDT
$112B
| $41.3M | 0.03% |
517,380
-14,922
| -3% | -$1.29M |
|
|
CYBR
153
DELISTED
CyberArk
CYBR
| $41.1M | 0.03% |
123,275
+21,877
| +22% | +$6.65M |
|
154
American Superconductor
AMSC
$1.59B
| $40.6M | 0.03% |
1,649,790
-456,605
| -22% | -$12.6M |
|
155
Savers
SVV
$1.88B
| $37.8M | 0.03% |
3,689,478
+3,138,844
| +570% | +$31.2M |
|
156
Twist Bioscience
TWST
$7.25B
| $36.1M | 0.03% |
777,537
-56,802
| -7% | -$2.57M |
|
157
Appian
APPN
$2.48B
| $36.1M | 0.03% |
1,095,052
-291,636
| -21% | -$10.4M |
|
158
AbCellera Biologics
ABCL
$2.12B
| $35.9M | 0.03% |
12,236,465
-658,238
| -5% | -$1.83M |
|
159
JFrog
FROG
$10.8B
| $35.1M | 0.03% |
1,194,717
-50,033
| -4% | -$1.52M |
|
160
Lufax Holding
LU
$1.3B
| $35.1M | 0.03% |
14,667,069
+49,964
| +0.3% | +$138K |
|
161
NovoCure
NVCR
$1.91B
| $34.6M | 0.03% |
1,161,310
-498,004
| -30% | -$10.5M |
|
162
Trupanion
TRUP
$1.18B
| $33.8M | 0.03% |
701,366
+147,341
| +27% | +$7.56M |
|
163
Aehr Test Systems
AEHR
$3.36B
| $33.7M | 0.03% |
2,023,559
+216,710
| +12% | +$2.89M |
|
|
JMIA
164
Jumia Technologies
JMIA
$767M
| $33.5M | 0.03% |
8,777,057
-288,834
| -3% | -$1.3M |
|
165
Ginkgo Bioworks
DNA
$521M
| $33M | 0.03% |
3,357,386
-1,195
| -0% | -$10.2K |
|
166
Hershey
HSY
$36.6B
| $31.1M | 0.02% |
183,716
+39,951
| +28% | +$7.16M |
|
167
Xometry
XMTR
$5.34B
| $30.3M | 0.02% |
+710,196
| New | +$20.1M |
|
168
dLocal
DLO
$4.24B
| $29.4M | 0.02% |
2,613,514
+1,360,183
| +109% | +$13.7M |
|
169
Wabtec
WAB
$49.3B
| $29M | 0.02% |
152,782
-9,606
| -6% | -$1.86M |
|
170
STAAR Surgical
STAA
$1.21B
| $28M | 0.02% |
1,153,886
-306,599
| -21% | -$8.76M |
|
171
IPG Photonics
IPGP
$3.84B
| $27.3M | 0.02% |
375,546
+95,199
| +34% | +$7.31M |
|
172
Tandem Diabetes Care
TNDM
$1.56B
| $26.9M | 0.02% |
746,109
+523,843
| +236% | +$17.7M |
|
173
Booking.com
BKNG
$161B
| $26.7M | 0.02% |
134,375
-1,475
| -1% | -$284K |
|
174
Eversource Energy
ES
$27.2B
| $26.1M | 0.02% |
454,384
-81,803
| -15% | -$5.1M |
|
175
Paychex
PAYX
$42.7B
| $25.4M | 0.02% |
+181,359
| New | +$25.8M |
|
Similar funds
Baillie Gifford & Co's Q4 2024 Portfolio in Review
As of Q4 2024, Baillie Gifford & Co held 285 positions worth $130B, down 2.6% from $134B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Baillie Gifford & Co withdrew a net $8.81B in Q4 2024, closing 14 positions and reducing 181 holdings. Its most notable exit was Mettler-Toledo International, an estimated $145M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 31% of assets, down from 33% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Baillie Gifford & Co opened a new position in DraftKings worth $247M.
- Baillie Gifford & Co's largest Q4 2024 buy was DraftKings: 6,633,458 shares worth $247M.
- Baillie Gifford & Co added most to Applovin in Q4 2024, an estimated $1.01B increase.
- Baillie Gifford & Co's biggest Q4 2024 reduction was Tesla, cutting an estimated $1.68B.
- Baillie Gifford & Co fully exited Mettler-Toledo International in Q4 2024, selling an estimated $145M.
- Baillie Gifford & Co's ten largest holdings make up 42% of its $130B portfolio in Q4 2024.
- Baillie Gifford & Co opened 8 new positions and closed 14 in Q4 2024.
- Baillie Gifford & Co's portfolio value fell 2.6% quarter-over-quarter to $130B.
Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.